Novo Nordisk A/S
NVO
$126.85
$1.060.84%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -3.41% | 15.64% | -0.57% | 52.91% | -4.30% |
| Total Depreciation and Amortization | -74.36% | 15.93% | 28.43% | 74.89% | -48.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -182.81% | -60.94% | -39.77% | 361.88% | -139.96% |
| Change in Net Operating Assets | -182.03% | 390.49% | 60.15% | -3,379.26% | 97.16% |
| Cash from Operations | -76.95% | 43.28% | -2.80% | 340.41% | -70.29% |
| Capital Expenditure | -59.56% | 0.90% | -27.01% | 0.77% | -55.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.21% | -117.53% | -76.81% | -12.99% | -6.28% |
| Cash from Investing | -9.85% | -42.56% | -41.65% | 49.66% | -183.15% |
| Total Debt Issued | -- | -- | -- | -- | 416.67% |
| Total Debt Repaid | -36.02% | 30.03% | 21.97% | -113.39% | 25.33% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -58.95% | 30.40% | -69.71% | 31.04% | -63.18% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 100.00% | -- | 100.00% | -- | 100.00% |
| Other Financing Activities | -- | -- | -200.00% | -- | -- |
| Cash from Financing | 49.58% | -57.46% | 38.09% | -182.09% | 46.60% |
| Foreign Exchange rate Adjustments | -149.43% | 742.77% | 74.94% | 67.31% | -293.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -284.30% | 25.11% | 194.85% | 115.69% | -400.08% |
